Investigational drug · Phase 3
phentolamine vehicle
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Mesopic Vision, Night Vision Loss, Presbyopia.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
13
Any phase or sponsor naming "phentolamine vehicle"
First trial start
2024
Apr 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "phentolamine vehicle", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mesopic Vision
- Night Vision Loss
- Presbyopia
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "phentolamine vehicle" as an intervention, largest first.
- OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual AcuityPivotal-lookingRecruiting
Opus Genetics, IncIndustry
NCT07140783 · 580 participants (planned) · Start Sep 2, 2025 · Primary completion Aug 2027
Drug: 0.75% Phentolamine Ophthalmic Solution; Placebo · For: Vision Loss Night; Vision Disorders
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 20 sites in all
- Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With PresbyopiaPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT06542497 · 569 participants · Start Aug 15, 2024 · Primary completion Apr 3, 2025
Drug: 0.75% phentolamine ophthalmic solution; Placebo · For: Presbyopia
Sites: Chandler, Arizona; Mesa, Arizona; Phoenix, Arizona · 39 sites in all
- Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)Pivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT05134974 · 368 participants · Start Nov 18, 2021 · Primary completion Mar 18, 2022
Drug: Phentolamine Ophthalmic Solution 0.75%; Phentolamine Ophthalmic Solution Vehicle · For: Mydriasis; Dilation
Sites: Newport Beach, California; Westminster, California; Delray Beach, Florida · 15 sites in all
- Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With PresbyopiaPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT05646719 · 333 participants · Start Dec 22, 2022 · Primary completion Oct 11, 2023
Drug: Phentolamine Opthalmic Solution 0.75%; Low dose pilocarpine · For: Presbyopia
Sites: Phoenix, Arizona; Azusa, California; Newport Beach, California · 26 sites in all
- Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual DisturbancesPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT06349759 · 200 participants · Start Apr 1, 2024 · Primary completion Apr 17, 2025
Drug: phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist; Placebo · For: Mesopic Vision; Night Vision Loss
Sites: Pheonix, Arizona; Scottsdale, Arizona; Bakersfield, California · 25 sites in all
- Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced MydriasisPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT04620213 · 185 participants · Start Nov 18, 2020 · Primary completion Dec 23, 2020
Drug: Phentolamine Ophthalmic Solution 0.75% · For: Mydriasis; Dilation
Sites: Newport Beach, California; San Diego, California; Longwood, Florida · 12 sites in all
- Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With PresbyopiaPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT04675151 · 150 participants · Start Feb 15, 2021 · Primary completion May 17, 2021
Drug: Phentolamine Ophthalmic Solution 0.75%; Pilocarpine · For: Presbyopia
Sites: Laguna Hills, California; Newport Beach, California; Crystal River, Florida · 17 sites in all
- Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision DisturbancesPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT04638660 · 144 participants · Start Dec 30, 2020 · Primary completion May 19, 2022
Drug: Phentolamine Ophthalmic Solution 0.75%; Phentolamine Ophthalmic Solution Vehicle (Placebo) · For: Dim Light Vision Disturbances
Sites: Newport Beach, California; Petaluma, California; Jacksonville, Florida · 17 sites in all
Opus Genetics, IncIndustry
NCT01703559 · 60 participants · Start Sep 9, 2011 · Primary completion Apr 16, 2012
Drug: Phentolamine Mesylate Ophthalmic Solution 1.0%; Phentolamine Mesylate Ophthalmic Solution 0.5% · For: Night Vision Complaints; Decrease in Night Vision; Disturbance; Vision, Loss
Sites: Phoenix, Arizona
Opus Genetics, IncIndustry
NCT03960866 · 39 participants · Start May 28, 2019 · Primary completion Sep 11, 2019
Drug: Phentolamine Mesylate Ophthalmic Solution 1% · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Mission Hills, California; Morrow, Georgia; Ann Arbor, Michigan · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.